The AZD1222 vaccine against coronavirus, produced by the University of Oxford in collaboration with AstraZeneca, resulted in an average efficacy of 70%.
This was reported by the press service of AstraZeneca.
"The combined analysis from both dosing regimens (n=11,636) resulted in an average efficacy of 70%. All results were statistically significant (p<=0.0001). More data will continue to accumulate and additional analysis will be conducted, refining the efficacy reading and establishing the duration of protection,” the statement said.
Clinical trials of the AZD1222 vaccine were performed in the United Kingdom and Brazil. In total, more than 20,000 volunteers took part in them.
As we reported earlier, this year, the Belarusian government intends to start the production of the Russian vaccine against coronavirus.
"In the lab conditions, the first batch will appear already this year, I'm sure. Maybe not on the facilities of Belmedpreparaty (state-run drug company, - 112 International), on a different enterprise. But this is going to happen this year," reads the message.